Charles Newton
Finanzdirektor/CFO bei LYELL IMMUNOPHARMA, INC.
Vermögen: 90 418 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Richard Klausner | M | 72 | 6 Jahre | |
Heather Turner | F | 51 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 5 Jahre |
Chip Baird | M | 52 | - | |
Nick Leschly | M | 51 | 3 Jahre | |
Catherine Friedman | F | 63 | 20 Jahre | |
Denny Lanfear | M | 68 | 14 Jahre | |
Lynn Seely | M | 65 | 3 Jahre | |
Daniel Lynch | M | 65 | 3 Jahre | |
Stig Hansen | M | 59 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 16 Jahre |
Daniel Simkowitz | M | 57 | 24 Jahre | |
Timothy Kutzkey | M | 49 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 14 Jahre |
Jeff Brodsky | M | 59 | 14 Jahre | |
James Gorman | M | 65 | 18 Jahre | |
Jill O'Donnell-Tormey | M | 68 | 2 Jahre | |
Ellen Rose | F | - | 3 Jahre | |
Frederick Pollock | M | 44 | 18 Jahre | |
Matthew Lang | M | 48 | 1 Jahre | |
Mark Stolper | M | 52 | 3 Jahre | |
Aetna Wun Trombley | M | 45 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 8 Jahre |
Denice Torres | F | 64 | 3 Jahre | |
Sarah Glickman | F | 54 | 3 Jahre | |
Wei Lin | M | 63 | 1 Jahre | |
Kimberly Commins-Tzoumakas | F | 56 | 4 Jahre | |
Marcela Maus | M | 48 | 3 Jahre | |
Jenn Snyder | M | - | - | |
Kelly Boothe | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Stephen Hill | M | 53 | 5 Jahre | |
Teresa Jurgensen | F | - | - | |
Bryan Mcmichael | M | 46 | 3 Jahre | |
Michael A. Fleming | M | - | 10 Jahre | |
Elizabeth Nabel | M | 72 | 3 Jahre | |
Minako Pazdera | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 Jahre |
Ali Satvat | M | 46 | 10 Jahre | |
Michael Gray | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 Jahre |
Otis Brawley | M | 64 | 3 Jahre | |
William Rieflin | M | 64 | 4 Jahre | |
Peter Svennilson | M | 62 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 4 Jahre |
Robert Nelsen | M | 60 | 6 Jahre | |
Lee Newcomer | M | 71 | 2 Jahre | |
Timothy Garnett | - | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 Jahre |
Hans Bishop | M | 59 | 6 Jahre | |
Eric Grossman | M | 57 | 18 Jahre | |
Anne Phillips | M | 70 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 Jahre |
Timothy Garnett | M | 63 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 Jahre |
Mats Wahlström | M | 70 | 12 Jahre | |
James Howland | M | - | 16 Jahre | |
Jonathan Starbecker | M | - | 18 Jahre | |
Richard L. Hameister | M | - | 3 Jahre | |
Heidi Brumbach | F | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 Jahre |
Susan Abu-Absi | M | - | - | |
Steven H. Bernstein | M | - | 2 Jahre | |
Paul Reider | M | 55 | 3 Jahre | |
Karen Kotz | F | - | 2 Jahre | |
Morgan Adams | M | - | - | |
Theresa M. LaVallee | M | 57 | 3 Jahre | |
Rosh Dias | M | - | 2 Jahre | |
Manu Chakravarthy | M | 50 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 3 Jahre |
Richard D. Goold | M | 64 | 5 Jahre | |
Gary Lee | M | 47 | 2 Jahre | |
Rebecca Sunshine | F | 61 | 10 Jahre | |
Kathy Bergsteinsson | F | - | 19 Jahre | |
Elizabeth Pingpank | F | - | - | |
Michael Ryan | M | - | 1 Jahre | |
Katy L. Huberty | F | - | 24 Jahre | |
David H. Schubert | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Taylor Henricks | M | - | 17 Jahre | |
Georgia Erbez | F | 57 | - | |
Frank Ducomble | M | - | 18 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jonathan Pruzan | M | 55 | 18 Jahre | |
Elizabeth Homans | F | 58 | - | |
Robert Scott | M | 78 | 2 Jahre | |
Thomas R. Nides | M | 63 | 5 Jahre | |
McDavid Stilwell | M | 53 | 3 Jahre | |
Edward A. Brennan | M | 90 | - | |
Thomas Kelleher | M | 67 | 15 Jahre | |
Orin Port | M | - | 9 Jahre | |
Sherrese Soares | F | 47 | 10 Jahre | |
Vladimir Vexler | M | 66 | 10 Jahre | |
Carl G Bauer-Schlichtegroll | M | - |
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | 3 Jahre |
Myles Lambert | M | 49 | 4 Jahre | |
Dame Amelia Fawcett | F | 67 | 16 Jahre | |
Robert Stockton | M | - | 1 Jahre | |
Nadav Zohar | M | 59 | 7 Jahre | |
John Carl Hahn | M | 65 | 11 Jahre | |
Kevin Mailender | M | 46 | - | |
Jaime Sanchez Yarza | M | - | - | |
Charles Phillips | M | 64 | 4 Jahre | |
James Rosenthal | M | 70 | 8 Jahre | |
Donald T. Nicolaisen | M | 79 | 11 Jahre | |
Gary W. Parr | M | 67 | 9 Jahre | |
Hutham Olayan | F | 69 | 15 Jahre | |
Philip J. Purcell | M | 80 | 19 Jahre | |
Laura Tyson | M | 76 | 19 Jahre | |
Robert Wood Jones | M | 73 | 32 Jahre | |
Carroll A. Reddic | M | 58 | 14 Jahre | |
Gary G. Lynch | M | 73 | 5 Jahre | |
Raymond A. Harris | M | 67 | - | |
Howard Davies | M | 73 | - | |
Klaus Svendsen | M | - | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 99 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Charles Newton
- Persönliches Netzwerk